A Phase 1b, Open-Label, Dose-Optimization Trial of an Adenoviral-vector Based Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 and dsRNA Adjuvant Administered Orally to Healthy Volunteers

Trial Profile

A Phase 1b, Open-Label, Dose-Optimization Trial of an Adenoviral-vector Based Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 and dsRNA Adjuvant Administered Orally to Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2018

At a glance

  • Drugs Norovirus vaccine (Primary)
  • Indications Norovirus infections
  • Focus Adverse reactions
  • Sponsors Vaxart
  • Most Recent Events

    • 29 May 2018 Status changed from recruiting to completed.
    • 02 Mar 2018 According to Vaxart media release, data from this trial will be presented at the upcoming 18th International Congress on Infectious Diseases (ICID).
    • 30 Oct 2017 Results presented in a Vaxart media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top